Drug
Argatroban clinical trials
Also written Novastan.
- studies test it
- 22
- open now
- 1
- in phase 3
- 4
- first study started
- 2002
Keep track of what changes. Save the argatroban studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
22 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2005 | 2 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 4
- Phase 4
- 11
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 17
Tanabe Pharma Corporation (2) · Medical University of Vienna (2) · The University of Texas Health Science Center, Houston (2) · Tanabe Pharma GmbH (1) · Washington University School of Medicine (1) · Beijing Chao Yang Hospital (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · General Hospital of Shenyang Military Region (1)
Often tested with
Tested in the same studies.
Eptifibatide (1) · Heparin, Low-Molecular-Weight (1) · Enoxaparin (1) · Warfarin (1) · Lepirudin (1)
Studies
Open first, then newest update. How each study uses argatroban is read from its arms, and is right about nine times in ten.
Testing it · 22
- Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO SupportRecruitingPhase 4Medical University of ViennaNCT06442267Written as Argatroban, 1 Mg/mL Intravenous Solution
- Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type IICompletedPhase 2Tanabe Pharma CorporationNCT00861692Written as argatroban
- Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)CompletedPhase 2Tanabe Pharma CorporationNCT00508924Written as Argatroban
- Safety of Argatroban Infusion in Conduction DisturbancesCompletedPhase 4Tanabe Pharma GmbHNCT05740371Written as Argatroban
- Multi-arm Optimization of Stroke ThrombolysisCompletedPhase 3Washington University School of MedicineNCT03735979Written as Argatroban
- Safety and Feasibility of Argatroban As Anticoagulant in Adults with ECMOCompletedPhase 2/3Medical University of ViennaNCT05226442Written as Argatroban
- Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMOCompletedNot applicableBeijing Chao Yang HospitalNCT04925167Written as Argatroban
- Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)TerminatedPhase 4Weill Medical College of Cornell UniversityNCT04406389Written as Argatroban
- Efficacy Argatroban in Ischemic Stroke With Early Deterioration (EASE)CompletedPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT04275180Written as Argatroban
- Argatroban Plus R-tPA for Acute Ischemic StrokeCompletedPhase 4General Hospital of Shenyang Military RegionNCT03740958Written as Argatroban
- Thromboprophylaxis After Surgery for Gynecologic Malignancy in ChinaCompletedPhase 3Huazhong University of Science and TechnologyNCT02935530Written as Argatroban
- Argatroban in Critically Ill Patients With Heparin ResistanceCompletedPhase 2Medical University InnsbruckNCT01734252Written as Argatroban
- Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft OcclusionTerminatedPhase 4Massachusetts General HospitalNCT01246011Written as Argatroban and warfarin
- Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in StrokeCompletedPhase 2The University of Texas Health Science Center, HoustonNCT02448069Written as Argatroban
- Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute StrokeTerminatedPhase 2Andrew D. Barreto, MDNCT01464788Written as Low Dose Argatroban
- Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery StentingCompletedPhase 4Jinling Hospital, ChinaNCT01163604Written as Argatroban
- Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery StentingCompletedPhase 4Xinfeng LiuNCT01980316Written as Argatroban
- Argatroban Stroke Treatment - A Pilot Safety StudyCompletedPhase 1/2The University of Texas Health Science Center, HoustonNCT00268762Written as argatroban
- Argatroban Versus Lepirudin in Critically Ill PatientsTerminatedPhase 4Heinrich-Heine University, DuesseldorfNCT00798525Written as Argatroban
- Efficacy and Safety Study of Argatroban to Treat Heparin-Induced ThrombocytopeniaCompletedPhase 3Ministry of Health, Labour and Welfare, JapanNCT00198588Written as argatroban
See all 22 studies that test argatroban →
As the comparator · 2 — what is tested is compared with argatroban
- A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human SubjectsCompletedPhase 1Veralox TherapeuticsNCT05325346Written as Argatroban
- Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs ArgatrobanTerminatedPhase 3Aspen Global IncorporatedNCT03809481Written as Argatroban
Codes
What other systems call argatroban · ClinicalTrials.gg INT002967
- MeSH (NLM) C031942argatrobanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) IY90U61Z3SARGATROBANConfirmed FDA, NLM, Wikidata
- RxNorm 15202One source FDA
- Wikidata Q59400516argatroban monohydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28833ArgatrobanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C031942 | argatroban | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | IY90U61Z3S | ARGATROBAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 15202 | — | One source FDA |
| Wikidata | Q59400516 | argatroban monohydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28833 | Argatroban | One source FDA |
Also registered as argatroban anhydrous (UNII OCY3U280Y3 · RxNorm 1546207), argatroban anhydrous, (21r)- (UNII 0DW7MIH1VX · RxNorm 15202), argatroban anhydrous, (21s)- (UNII 4YBM839JAC) and argatroban, (21r)- (UNII 88X69347Z5).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.